Labcorp offers comprehensive global testing to support all aspects of your neurodegenerative therapeutic development 

Innovative Biomarker Testing 
including pTau217, GFAP, NfL and Aβ 42/40

Deep Therapeutic Expertise 
across neurodegenerative diseases like Alzheimer's, Parkinson's and more

Comprehensive Clinical Trial Testing 
from biomarker discovery to companion diagnostic commercialization

Labcorp has extensive experience helping clients develop promising new therapies for neurodegenerative disease, supporting 100 % of the 2023 FDA-approved therapies.

Key Biomarkers for Neurodegenerative Therapy Development:

Biomarker Associated Diseases
NfL Neurodegeneration: MS, ALS, AD, PD, FTD (frontotemporal dementia), HAND (HIV associated neurocognitive disorder), COVID-19 associated neurological disorders, concussion/mTBI
GFAP Neurodegeneration: MS, AD, NMOSD (neuromyelitis optica spectrum disorder), COVID-19 associated neurological disorders, concussion/mTBI
pTau217 AD
pTau181 AD
Total tau Tauopathies: AD, FTD with Parkinsons (PD), PSP (progressive supranuclear palsy), HAND, concussion/mTBI
Neuro 3-plex: Amyloid beta (1-42), Amyloid beta (1-40), total tau AD, HAND
Neuro 4-plex E: Amyloid beta (1-42), Amyloid beta (1-40), NfL and GFAP AD
Neuro 4-plex A: NfL, GFAP, Total Tau, UCH-L1 Concussion/mTBI
a-synuclein PD, AD
Amyloid beta (1-40) AD
Amyloid beta (1-42) AD
Amyloid beta 42/40 AD
pTau231 AD
Cytokine 3-plex: IL-6, TNFa, IL-10 AD (inflammation)

One partner to achieve your next Alzheimer’s advancement

Check out our Alzheimer’s-specific biomarker offerings.

Leverage Labcorp’s deep knowledge supporting 90+ Alzheimer’s disease protocols­–in 45+ countries with 96,000+ patients–in the last 5 years​ alone

Access holistic and specialized neurology expertise for support from strategy to lab with our Biomarker Solution Center and global translational biomarker scientists

Experience Alzheimer's clinical trial testing delivered by a global laboratory network with critical sample management and logistics capabilities

Let's discuss your program to determine how we can help accelerate you neurodegenerative therapy innovation.

Explore More Neurodegenerative Capabilities

ALS, Ataxias, & Huntington's

Genetics can play a significant role in the development of certain neurodegenerative diseases. In some cases, genetic testing may help confirm a diagnosis.


Finding a way to diagnose Alzheimer's earlier and easier is a key goal for Labcorp.

Muscular Dystrophy

Characterized by progressive muscle loss and weakness, our tests can detect the genetic mutations that cause the most common forms.

Multiple Sclerosis

While no single test can diagnose multiple sclerosis, lab tests may help doctors rule out other diseases and confirm a diagnosis.